A phase Ib/IIa, randomised, double-blind, multicentre trial to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the treatment of patients with community-acquired bacterial pneumonia admitted to the intensive care unit
Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Bruno François(Inserm), Miguel Sánchez García(Hospital Clínico San Carlos), Tom van der Poll(Amsterdam Neuroscience), Eleuterio Lombardo, Kathy-Ann Cadogan(Takeda (United States)), Olga de la Rosa
Cited by 23
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
Sepsis: a roadmap for future research
|The Lancet Infectious Diseases|2015|1k